R&D: new licenses, patents and registered trademarks
January 18, 2018 at 02:59 pm EST
Share
National Securities Market Comission Markets Directorate General c/ Edison núm. 4
28006 Madrid
Colmenar Viejo (Madrid), January 18, 2018
Pursuant to article 228 of the consolidated text of the Spanish Securities Market Act, we hereby inform you of the following SIGNIFICANT EVENT:
"Pharma Mar, S.A. announces the results of the Phase III clinical trial (CORAIL) with Zepsyre® (lurbinectedin) in platinum-resistant ovarian cancer patients.
The CORAIL trial, comparing Zepsyre® versus topotecan or PLD (liposomal doxorubicin) in platinum resistant ovarian cancer patients has not met the primary end-point of the trial, which was PFS (Progression Free Survival).
The antitumoral activity of the three compounds Zepsyre®, topotecan and PLD, in terms of PFS, has been the same.
In the CORAIL trial Zepsyre® has demonstrated a better safety profile than the control arm.
Results of this trial will be presented at future oncology congresses."
Pharma Mar S.A. Avda. de los Reyes, 1 P.I. La Mina 28770 Colmenar Viejo (Madrid) Spain
Pharma Mar SA published this content on 18 January 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 18 January 2018 19:59:00 UTC.
Original documenthttps://www.pharmamar.com/2018/01/18/rd-new-licenses-patents-and-registered-trademarks-7/
Public permalinkhttp://www.publicnow.com/view/5ACA99DFF00F6BA6B77E14276F0D9666D1311835
Pharma Mar SA is a Spain-based integrated biopharmaceutical company focused on oncology and committed to research and development (R&D) of antitumor drugs of marine origin. The Company, through its subsidiaries, operates three business segments: Oncology, Diagnostics and RNA interference. The Oncology segment encompasses research, develop and market anti-tumor drugs. The Diagnostics segment includes the development and marketing of diagnostic kits. The RNA interference segment consist of the development of drugs with therapeutic activity based on reducing or silencing gene expression. The Companyâs product portfolio includes Yondelis and ZEPZELCA. Yondelis (trabectedin) is indicated for the treatment of advanced soft tissue sarcoma, as well as for the treatment of relapsed platinum-sensitive ovarian cancer. ZEPZELCA (lurbinectedin) is indicated for the treatment of metastatic small cell lung cancer (SCLC) with disease progression. The Company is active globally.
PHARMA MAR, S.A. 
